lazanda Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Lazanda, and what generic alternatives are available?
Lazanda is a drug marketed by Btcp Pharma and is included in one NDA. There are five patents protecting this drug.
This drug has sixty-two patent family members in thirty countries.
The generic ingredient in LAZANDA is fentanyl citrate. There are thirty-one drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the fentanyl citrate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Lazanda
A generic version of lazanda was approved as fentanyl citrate by HIKMA on July 11th, 1984.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for lazanda?
- What are the global sales for lazanda?
- What is Average Wholesale Price for lazanda?
Summary for lazanda
International Patents: | 62 |
US Patents: | 5 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 34 |
Clinical Trials: | 5 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for lazanda |
What excipients (inactive ingredients) are in lazanda? | lazanda excipients list |
DailyMed Link: | lazanda at DailyMed |
![lazanda drug patent expirations Drug patent expirations by year for lazanda](/p/graph/s/t/lazanda-patent-expirations.png)
![Drug Prices for lazanda](/p/graph/drug-price/lazanda.png)
Recent Clinical Trials for lazanda
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of California, San Diego | Phase 2 |
Joseph Ma | Phase 2 |
Defense and Veterans Center for Integrative Pain Management | Phase 4 |
US Patents and Regulatory Information for lazanda
lazanda is protected by five US patents.
Patents protecting lazanda
Method of managing or treating pain
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER
Method of managing or treating pain
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER
Intranasal spray device containing pharmaceutical composition
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Container
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Intranasal spray device containing pharmaceutical composition
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Btcp Pharma | LAZANDA | fentanyl citrate | SPRAY, METERED;NASAL | 022569-001 | Jun 30, 2011 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Btcp Pharma | LAZANDA | fentanyl citrate | SPRAY, METERED;NASAL | 022569-003 | Dec 21, 2015 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Btcp Pharma | LAZANDA | fentanyl citrate | SPRAY, METERED;NASAL | 022569-001 | Jun 30, 2011 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Btcp Pharma | LAZANDA | fentanyl citrate | SPRAY, METERED;NASAL | 022569-002 | Jun 30, 2011 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for lazanda
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Btcp Pharma | LAZANDA | fentanyl citrate | SPRAY, METERED;NASAL | 022569-002 | Jun 30, 2011 | ⤷ Sign Up | ⤷ Sign Up |
Btcp Pharma | LAZANDA | fentanyl citrate | SPRAY, METERED;NASAL | 022569-001 | Jun 30, 2011 | ⤷ Sign Up | ⤷ Sign Up |
Btcp Pharma | LAZANDA | fentanyl citrate | SPRAY, METERED;NASAL | 022569-002 | Jun 30, 2011 | ⤷ Sign Up | ⤷ Sign Up |
Btcp Pharma | LAZANDA | fentanyl citrate | SPRAY, METERED;NASAL | 022569-001 | Jun 30, 2011 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for lazanda
See the table below for patents covering lazanda around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Israel | 169480 | תכשירי רוקחות המכילים פנטניל למתן תוך-אפי (Pharmaceutical compositions comprising fentanyl for intranasal delivery) | ⤷ Sign Up |
Australia | 7064798 | ⤷ Sign Up | |
Japan | 2014511307 | ⤷ Sign Up | |
Mexico | 345813 | ENVASE MEJORADO. (IMPROVED CONTAINER.) | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for lazanda
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0836511 | SPC/GB06/022 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: FENTANYL HYDROCHLORIDE; REGISTERED: UK EU/1/05/326/001 20060124 |
1635783 | 122014000024 | Germany | ⤷ Sign Up | PRODUCT NAME: FENTANYL IN ALLEN DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORMEN; REGISTRATION NO/DATE: EU/1/10/644/001-004 20100831 |
1635783 | CA 2014 00016 | Denmark | ⤷ Sign Up | PRODUCT NAME: FENTANYL I EN HVILKEN SOM HELST AF DE FORMER, DER ER BESKYTTET AF GRUNDPATENTET; REG. NO/DATE: EU/1/10/644/001-006 20100831 |
1769785 | C300521 | Netherlands | ⤷ Sign Up | PRODUCT NAME: FENTANYL; REG NO/DATE: EU/2/11/127/001 20111006 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |